509 A phase I clinical trial of RNF43 peptide-specific immune cell therapy combined with low dose cyclophosphamide for patients with advanced solid tumors
Yasuhiro Hijikata(Kyushu University Hospital), Hiroaki Ogata, Mutsunori Murahashi(Jikei University School of Medicine), Kazumasa Yamada(Hiroshima University), Kaori Tani, Teiji Okazaki
Cited by 0
Related Papers
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors
|Clinical Immunology|2016|62
Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis
|Cancer Immunology Research|2018|36
HRX gene rearrangement in acute lymphoblastic leukemia after adjuvant chemotherapy of breast cancer [letter; comment]
|Blood|1993|34
RBPJ and MAML3: Potential Therapeutic Targets for Small Cell Lung Cancer
|Anticancer Research|2018|20